A number of firms have modified their ratings and price targets on shares of Roivant Sciences (NASDAQ: ROIV) recently:
- 9/19/2024 – Roivant Sciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 9/19/2024 – Roivant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
- 9/11/2024 – Roivant Sciences had its price target raised by analysts at Bank of America Co. from $12.00 to $12.50. They now have a “neutral” rating on the stock.
- 9/11/2024 – Roivant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
- 9/9/2024 – Roivant Sciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
- 8/19/2024 – Roivant Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Roivant Sciences Trading Down 0.7 %
Shares of Roivant Sciences stock opened at $11.92 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24. The stock has a market cap of $8.81 billion, a price-to-earnings ratio of 2.36 and a beta of 1.25. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $11.45 and a 200-day simple moving average of $11.06.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $30.72 million. During the same period in the prior year, the company earned ($0.38) earnings per share. The business’s revenue was up 155.1% compared to the same quarter last year. On average, equities analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.
Institutional Trading of Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
- Five stocks we like better than Roivant Sciences
- Quiet Period Expirations Explained
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Are Penny Stocks a Good Fit for Your Portfolio?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Roivant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.